Search Results
Your search for ,maY matches 16615 pages
Showing 11651 - 11700Occult Metastasis on Immunohistochemistry May Affect Survival in Stage I NSCLC
Mature results of the Cancer and Leukemia Group B 9761/Alliance study, reported in the Journal of Clinical Oncology by Martin et al, indicate that occult metastases detected by immunohistochemistry in N2 lymph nodes may be associated with poorer overall survival after resection in clinical stage I...
Closing the Clinical Trial Gap for Adolescents and Young Adults With Cancer
Although overall survival rates for patients with cancer continue to soar—with 14.5 million cancer survivors today1—most of that gain is among pediatric and older adult patients. For adolescents and young adults with cancer—defined by the National Cancer Institute (NCI) as those in the 15- to...
Geriatric Assessment of Transplant-Ineligible Older Adults With Multiple Myeloma: A Novel Approach in the Era of Novel Agents
Myeloma is a disease of aging, with a median age at diagnosis in the United States of 69 years.1 As the population ages, forecasts estimate that, within 20 years, 3 of every 4 people diagnosed with multiple myeloma in the United States will be between the ages of 64 and 84 years.2 In anticipation...
Is This the Dawn of Cancer Biosimilars?
The Patient Protection and Affordable Care Act, signed into law in 2010, did more than make it possible for millions of Americans to afford health care; it also established an abbreviated approval pathway for biologic products that are “biosimilar” to, or shown to be “interchangeable” with, a U.S....
Obinutuzumab in Relapsed or Refractory Follicular Lymphoma
On February 26, 2016, obinutuzumab (Gazyva) was approved for use in combination with bendamustine (Bendeka, Treanda) followed by obinutuzumab monotherapy for treatment of patients with follicular lymphoma who have relapsed after or are refractory to a rituximab (Rituxan)-containing regimen.1,2...
Conquering Cancer With Dr. Kim
There are many different ways to treat cancer: surgery, radiation therapy, chemotherapy, and more, sometimes used alone and sometimes in combination. But, in certain circumstances, the best treatment option for a patient may not look much like treatment at all. Instead of attempting to eliminate...
Cancer Survivorship Research: Learning From the Past to Improve Future Outcomes
Soon after effective therapies for some childhood malignancies were first identified, early leaders in our field had concerns about what would happen to surviving patients as they aged. In 1975, Giulio D’Angio, MD, one of the founders of modern pediatric radiation oncology, presciently called for...
Douglas A. Levine, MD, FACOG, FACS, Appointed Director of Gynecologic Oncology at NYU Langone
Douglas A. Levine, MD, FACOG, FACS, will join the faculty of NYU Langone Medical Center as Director of the Division of Gynecologic Oncology at its Laura and Isaac Perlmutter Cancer Center and the Department of Obstetrics and Gynecology, effective May 15, 2016. Dr. Levine brings an exceptional...
Expert Point of View: David Raben, MD
“Proton therapy may very well offer reduced late toxicities. Reflecting back on past reirradiation studies both within and outside of the cooperative groups, it seems that the late toxicities in this retrospective study were somewhat similar,” said David Raben, MD, Professor of Radiation Oncology...
Markedly Improved Toxicity Rates With Proton-Beam Reirradiation for Recurrent Head and Neck Cancer
Proton-beam radiation therapy may be an attractive option for reirradiation of recurrent head and neck cancer, with encouraging disease control and survival rates and improved toxicity rates compared to photon reirradiation, according to John Han-Chih Chang, MD. Most head and neck cancers present...
Study Supports an Immune Effect of Chemoradiation in Head and Neck Cancer
Definitive radiation, with or without chemotherapy, induces a combination of immune-stimulating and inhibitory effects in patients with squamous cell carcinoma of the head and neck, according to research presented by Jonathan Schoenfeld, MD, MPhil, MPH, at the 2016 Multidisciplinary Head and Neck...
Mutational Profile May Impact Treatment Decisions for Smokers With Human Papillomavirus–Positive Oropharyngeal Cancer
Smokers whose oropharyngeal tumors are positive for the human papillomavirus (HPV) might need more aggressive treatment for their disease, according to research presented by Jose Zevallos, MD, at the 2016 Multidisciplinary Head and Neck Cancer Symposium in Scottsdale, Arizona.1 Over time,...
Annual Report Cites Continued Decline in Most Cancer Mortality but Trends Toward Increased Liver Cancer Incidence, Mortality
Earlier this month, experts from four major institutions issued the annual Report to the Nation on the Status of Cancer (1975–2012). This year’s report showed that death rates continued to decline for all cancers combined, as well as for most cancer sites for men and women of all major racial and...
Surgeons—Yes, Surgeons—Have a Role in Translational Cancer Research
Surgeons are clearly more comfortable in the operating room than the laboratory, but there is a place for them in translational cancer research as well, according to one surgeon who has led cutting-edge research in pancreatic cancer. “Translational studies require access to patients, to tissue, and ...
Phone Triage System Offers Potential to Reduce Patient Visits to the Emergency Department for Cancer Treatment–Related Symptoms
A quality improvement initiative to reduce the reliance of patients on visits to the emergency department for treatment of side effects related to cancer treatment was reported to be highly effective, according to early findings from a new study. 1 The strategy, involving a telephone triage...
Regulators Embrace Immunotherapy
The Cancer Drug Development Forum exists to provide, as the name implies, a meeting place to bring together academia, the pharmaceutical industry, and most important regulators for full and frank discussions to facilitate anticancer drug development. In the recent past, the Cancer Drug Development...
Anticoagulation in Patients With Cancer: Understanding the Complexities of Prophylaxis and Management
Venous thromboembolic events are more prevalent in patients with cancer than in persons without it. Cancer is associated with a high rate of venous thromboembolism recurrence, bleeding, requirement for long-term anticoagulation, and reduced quality of life. Moreover, thrombosis is the second most...
Chronic Lymphocytic Leukemia: The Golden Drug Only for Golden Agers?
As reviewed in this issue of The ASCO Post, Burger and colleagues recently reported findings of the RESONATE-2 trial of ibrutinib (Imbruvica) vs chlorambucil (Leukeran) as initial therapy for elderly patients with chronic lymphocytic leukemia (CLL).1 The study met its primary endpoint of...
Little Effect of Pretreatment Renal Function on Outcomes in Older Women Receiving Chemotherapy for Early-Stage Breast Cancer
As reported by Lichtman et al in the Journal of Clinical Oncology, an ancillary study (Alliance A171201) of the CALGB 49907 trial showed no significant association of pretreatment creatinine clearance with grade ≥ 3 hematologic toxicity, dose modification, therapy completion, relapse-free...
Long-Term Follow-up of Prospective U.S. Cohorts Shows Reduced Risk of GI Tract Cancers With Regular Aspirin Use
In a long-term follow up of two large U.S. prospective cohorts reported in JAMA Oncology, Cao et al found that regular use of aspirin was associated with a reduced risk of gastrointestinal (GI) tract cancers. In 2015, the U.S. Preventive Services Task Force recommended the use of aspirin in...
Specific Form of CYP3A7 Gene Associated With Poor Outcomes for Patients With Several Cancer Types
Among patients with breast cancer, lung cancer, or chronic lymphocytic leukemia (CLL), those who had a specific form of the CYP3A7 gene (CYP3A7*1C) had worse outcomes compared with those who did not have CYP3A7*1C. This may be related to how the patients metabolize the therapeutics used to treat...
Processed Meat Consumption May Increase Risk of Breast Cancer for Latinas
Latinas who eat processed meats such as bacon and sausage may have an increased risk for breast cancer, according to a new study that did not find the same association among white women. The study, published by Kim et al in Cancer Causes & Control, suggests that race, ethnicity, genetics,...
Dietary Glycemic Index Linked to Lung Cancer Risk in Non-Hispanic White Populations
Consuming a diet with a high glycemic index was independently associated with an increased risk of developing lung cancer in non-Hispanic whites, according to a new epidemiologic study from The University of Texas MD Anderson Cancer Center. This research, published by Melkonian et al in Cancer...
No Significant Survival Advantage for Rigosertib in High-Risk Myelodysplastic Syndromes, but Subgroups May Benefit
As reported in The Lancet Oncology by Garcia-Manero et al, the phase III ONTIME trial showed that treatment with the Ras mimetic rigosertib did not significantly improve overall survival vs best supportive care in patients with high-risk myelodysplastic syndromes after failure of hypomethylating...
Study Evaluates Patient/Oncologist Perceptions of Whole-Exome Sequencing in Advanced Cancer
A majority of people with advanced cancer want to hear findings from DNA sequencing and to learn how those results may affect their health and treatment options, Dana-Farber Cancer Institute scientists report. Their findings were reported by Gray et al in Genetics in Medicine. The discovery...
Resensitization to Crizotinib via Acquisition of Lorlatinib ALK Resistance Mutation Reported in Patient With NSCLC
As reported by Shaw et al in The New England Journal of Medicine, a woman with metastatic ALK-rearranged non–small cell lung cancer (NSCLC) who had received multiple prior therapies, including the first- and second-generation ALK inhibitors crizotinib (Xalkori) and ceritinib (Zykadia),...
ASCO Report Finds U.S. Cancer Care System Ill-Equipped to Deliver New Advances to Patients
As the nation embarks on an ambitious “moonshot” to accelerate progress against cancer, our system for delivering today's cancer treatments must be better prepared to bring advances to all patients, warns a new report from ASCO. The State of Cancer Care in America: 2016, published...
Single Dose of Trastuzumab Kickstarts Immune Response in Certain Breast Cancers
A tumor’s immune response to a single dose of the HER2 inhibitor trastuzumab (Herceptin) predicted which patients with HER2-positive breast cancer would respond to the drug on a more long-term basis, according to the results of a study published by Varadan et al in Clinical Cancer Research....
Atezolizumab Active in Previously Treated Locally Advanced or Metastatic Urothelial Carcinoma
The anti–PD-L1 (programmed cell death ligand 1) antibody atezolizumab produced durable responses in a marked proportion of patients with previously treated locally advanced or metastatic urothelial carcinoma, according to a phase II trial reported in The Lancet by Rosenberg et al. The...
Severe Adverse Event Clusters Identified Using NCI Common Terminology Criteria in Advanced Prostate Cancer
Using the National Cancer Institute’s Common Terminology Criteria for Adverse Events (CTCAE), researchers from Columbia University, New York, and Fred Hutchinson Cancer Research Center, Seattle, identified six severe adverse events clusters in patients with advanced prostate cancer. The...
Combination Therapy May Be Better Than Radiotherapy Alone to Treat Aggressive Brain Cancer, According to Early Study
Radiotherapy effectively damages brain tumors, but the cancer cells can repair themselves in order to live on. Now, researchers at Sidney Kimmel Cancer Center at Thomas Jefferson University have tested a strategy that combines radiotherapy with a drug that shuts down the ability of tumor to mend...
Researchers Find Possible Association Between Oral Bacteria and Esophageal Cancer
University of Louisville School of Dentistry researchers have found that a bacterial species responsible for gum disease, Porphyromonas gingivalis, is present in 61% of patients with esophageal squamous cell carcinoma. The findings, published by Gao et al in Infectious Agents and Cancer, only...
Family Perspectives Support Advance Care Planning With Patient Preferences in End-of-Life Care
Three measures of aggressive end-of-life care “were associated with relatively large differences in family member–reported quality ratings for end-of-life care and a lower likelihood that patients with advanced-stage cancer received care congruent with their preferences,”...
Questions From Younger Patients About Colorectal Cancer Should Be Addressed Promptly
A study in Cancer1 finding an increasing rate of colorectal cancer among patients under the age of 50 should serve to raise awareness about the need for testing among those with “red-flag” symptoms and earlier screening for those at high risk, the study’s corresponding author, Samantha Hendren, MD, ...
‘Red-Flag’ Symptoms That Could Signal Colorectal Cancer in Patients Under 50 Years Old Should Be Taken Seriously
In clinical practice, Samantha Hendren, MD, MPH, has been “shocked by what a large proportion of patients we are seeing who are under 50 and presenting with colorectal cancer,” often with advanced disease due to delayed diagnosis. “And that is because patients and physicians don’t even think of...
Selected Abstracts From 2015 ASH Annual Meeting: Part 3
Here are several more abstracts selected from the proceedings of the 2015 American Society of Hematology (ASH) Annual Meeting and Exposition, focusing on the topic of anticoagulation and the cancer patient. For other selected abstracts from this conference, see the December 25, 2015, and the...
2016 Oncology Meetings
MARCH 2016 Methods in Clinical Research Workshop for Minority PhysiciansMarch 17-20 • Fort Lauderdale, FloridaFor more information:https://www.roswellpark.edu/education/diversity-clinical-research-workshop The 16th Multidisciplinary Management of Cancers: A Case-Based ApproachMarch 18-20 • Napa,...
Eribulin Mesylate in Advanced Liposarcoma Previously Treated With an Anthracycline
In the Clinic provides overviews of novel oncology agents, addressing indications, mechanisms, administration recommendations, safety profiles, and other essential information needed for the appropriate clinical use of these drugs. On January 28, 2016, eribulin mesylate (Halaven) was approved for...
Comprehensive Genomic Analysis Reveals New Genetic Insights Into Malignant Mesothelioma
Malignant mesothelioma is a rare but deadly form of cancer; the 5-year survival rate for patients diagnosed with the disease is between 5% and 10%. Although aggressive surgery can help some patients with early-stage mesothelioma, current treatments for patients with more advanced mesothelioma are...
Hyperthermic Laser Surgery Disrupts Blood-Brain-Barrier in Glioblastoma, Opening Path for Chemotherapy
Neurosurgeons at Washington University School of Medicine in St. Louis used hyperthermic laser ablation to shrink tumors in patients with recurrent glioblastoma and noted a temporary disruption of the blood-brain barrier, thereby enabling them to deliver chemotherapy to the peritumoral region....
Geriatric Assessment Is Key to Treatment Decisions for Patients 80 Years and Older With Breast Cancer
A review of major studies and the current literature underscored the role of geriatric assessment in making treatment recommendations for patients aged 80 years and older with early and metastatic breast cancer. The review was reported by Shachar et al in the Journal of Oncology Practice. The...
Expert Point of View: Kathy S. Albain, MD, FACP, FASCO, and Jame Abraham, MD
The general consensus of breast cancer experts of the initial findings of BCIRG-006 triggered a more judicious use of anthracyclines, and this trend continues. Kathy S. Albain, MD, FACP, FASCO, Professor of Medicine at Loyola University Chicago Stritch School of Medicine, Maywood, Illinois, said...
Final Analysis of BCIRG-006 Supports Use of Non–Anthracycline-Containing Regimen in Treatment of Women With Early Breast Cancer
The final analysis of the BCIRG-006 trial confirmed the long-term efficacy of trastuzumab (Herceptin) in early breast cancer and also validated the concept that anthracyclines increase toxicity and they are not always necessary for a good outcome.1 The 10-year follow-up of the landmark trial was...
Making the Most of Poster Sessions
Nathan A. Pennell, MD, PhD, an Associate Professor and Director of the Lung Cancer Medical Oncology Program at the Cleveland Clinic Taussig Cancer Institute and a Poster Walk leader at the 2015 ASCO Annual Meeting, offers advice for anyone planning to attend a Poster Session: Plan ahead. Make sure ...
2015 Palliative Care in Oncology Symposium Highlights
The Palliative Care in Oncology Symposium, held October 9–10, 2015, in Boston, Massachusetts, brought together more than 670 members of the cancer care community, including oncologists, radiologists, palliative care specialists, nurses, and patient advocates. Sessions delivered information on...
Conquer Cancer Foundation–Funded Research Published in High-Impact Journals
The Conquer Cancer Foundation of the American Society of Clinical Oncology (CCF) encourages grantees to share the results of their research to help advance progress against cancer. Publication in peer-reviewed journals is one of the most important ways for scientists to achieve recognition. That...
Advanced Imaging May Be Unnecessary for Many Women With Early Breast Cancer, but Rate of Such Testing Remains High
Up to 60% of the computed tomography (CT) scans, bone scans, and positron emission tomography (PET) scans performed for more than 29,000 Michigan women diagnosed with early breast cancer between 2008 and 2014 could not be medically justified based on retrospective record review, according to the...
Carfilzomib Plus Dexamethasone in Previously Treated Multiple Myeloma
In the Clinic provides overviews of novel oncology agents, addressing indications, mechanisms, administration recommendations, safety profiles, and other essential information needed for the appropriate clinical use of these drugs. On January 21, 2016, carfilzomib (Kyprolis) was approved for use in ...
CAR-T Cell Therapy May Have Role in Treating Multiple Myeloma
Among the burgeoning options for treating multiple myeloma could be an approach that is proving to be exciting in leukemia: CAR-T (chimeric antigen receptor T cells) therapy. Preliminary results of the first-in-humans study in myeloma were presented as a late-breaking abstract at the 2015 ASH...
Genomic Alterations in Primary Invasive Lobular Breast Cancer
In a study reported in the Journal of Clinical Oncology, Desmedt et al identified genomic alterations in invasive lobular breast cancer, including several that may serve as targets for current treatment and for treatment research. Invasive lobular breast cancer cells are characterized by...
